|
Targeted drug delivery, which also refers to drug targeting or site specific drug
delivery, is to site-specifically deliver or activate the therapeutic compounds
in the site of action. Thus, the targeted drug delivery is expected to enhance drug
efficacy by increasing local active drug concentration in disease tissues, and to
decrease side effect by minimizing drug exposure in normal tissues. Several targeted
drug delivery technologies have been studied for enhancing drug efficacy and reducing
drug toxicity, which have achieved certain degree of success. These technologies
include: Intratumoral drug administration, Liposomal drug delivery, Tumor-activated
prodrug therapy (TAP), Antibody-directed enzyme prodrug therapy (ADEPT), Gene-directed
enzyme prodrug therapy (GDEPT), Folate-targeted drug delivery, Transferrin targeted
drug delivery, Albumin-drug conjugate for targeted delivery, and prodrug targeted
delivery.
Prodrug strategies have traditionally been used to address ADMET liabilities of
marketed compounds or as tools in late-stage problem solving for drug development
candidates. However, prodrugs are now increasingly being integrated into early drug
discovery as a means of expanding the chemical space of drugable molecules.
The Targeted Drug Delivery and Prodrug Focus Group was evolved from prodrug focus
group, which was formed in 2004. The Targeted Drug Delivery and Prodrug Focus Group
affiliated with the following section: Physical Pharmacy and Biopharmaceutics (PPB),
Drug Design and Discovery (DDD), and Pharmacokinetics, Pharmacodynamics and Drug
Metabolism (PPDM).
The goals of the Targeted Drug Delivery and Prodrug Focus Group are to expand drug
targeting technologies and prodrug knowledge through education, impact the direction
of targeted drug delivery and prodrug research through long-range programming, encourage
interdisciplinary collaborations, encourage innovative use of new technologies to
solve drug targeting problems, and provide a common forum for universities, industry,
and government.
To achieve these goals, we will continue to build interdisciplinary programming
between PPB, DDD, and PPDM sections, develop a young and sustainable leadership
pool for the Targeted Drug Delivery and Prodrug Focus Group, plan an intermediate-range
program so researchers can anticipate future forums for innovative research, provide
an inclusive environment for programming ideas into workshops, symposia, roundtables,
and short courses; and foster interdisciplinary collaborations and research that,
in turn, would advance the discipline, health care, consumer interests, and AAPS
programming quality. To achieve this, the Targeted Drug Delivery and Prodrug Focus
Group will serve as a forum for targeted drug delivery and prodrug scientists/enthusiasts
in many areas including drug delivery and targeting; metabolism; chemical synthesis;
molecular biology; biotechnology; drug safety; clinical trial testing; as well as
drug approval and regulation.
Goals
The goals of the Targeted Drug Delivery and Prodrug Focus Group are to:
- expand targeted drug delivery and prodrug knowledge through education
- impact the direction of drug targeting and prodrug research through long-range programming
- encourage interdisciplinary collaborations in drug targeting technologies and prodrug
research
- encourage innovative use of new technologies to solve drug targeting and prodrug
problems
- provide a common forum for universities, industry, and government
To achieve these goals we will:
- develop interdisciplinary programming between PPB, PPDM & DDD
- develop a young and sustainable leadership pool for the Targeted Drug Delivery and
Prodrug Focus Group
- plan an intermediate-range program so researchers can anticipate future forums for
innovative research
- provide an inclusive environment for programming ideas into workshops, symposia,
roundtables, and short courses
- foster interdisciplinary collaborations and research that, in turn, would advance
the discipline, health care, consumer interests, and AAPS programming quality. Our
working assumption is that by providing such a forum for targeted drug delivery
and prodrug designers in the areas of:
- Targeted Drug Delivery
- Site specific drug activation
- Metabolism
- Chemical Synthesis
- Molecular Biology
- Biotechnology
- Drug Safety
- Clinical Trial Testing
- Drug Approval and Regulation
Drug targeting and Prodrugs will be used more often and sooner as a means of enhancing
drug efficacy, reducing drug toxicity, overcoming the physical/chemical liabilities
of active therapeutic agents so that more innovative therapies will reach the market
place.
Past Programming
- Prodrug approaches for organ specific targeted therapy
November 20, 2008
- Effective Interactions from Pre-IND to IND and Beyond: “getting your Ducks in the
Row” with the FDA
November 20, 2008
- The World Within and Beyond P-gp: Do we Underestimate or Overestimate P-gp?
November 19, 2008
- Transporters as Prodrug Carriers for Oral Drug Delivery
November 19, 2008
- Accurate Prediction of Metabolic DDI - from Preclinical Discovery to Clinical Development
November 19, 2008
- Tumor Imaging and Targeted Drug Delivery
November 19, 2008
- Rational Drug and Prodrug Design Via Computational Modeling
November 18, 2008
- PK/PD of Biologics: from Discovery to Successful Development
November 18, 2008
- Prodrug Approaches for Site-Specific Cellular Targets Roundtable
November 15, 2007
- Tumor-activated Prodrug and Tumor-targeting Technologies: ADEPT, GDEPT and PDEPT
to Increase Drug Efficacy and Reduce Drug Toxicity Roundtable
November 14, 2007
- Solving ADMET Problems with Prodrug, Soft-Drug & Co-Drugs Roundtable, November 2,
2006
Panel members: Howard Ando, Paul Erhardt, Peter Crooks
Moderators: Howard Ando and Tycho Heimbach
- Strategies & Technologies for Transdermal and Ocular Drug Delivery Roundtable, November
1, 2006
Panel members: Bo Michniak-Kohn, Diane Tang-Liu, Ken Sloan
Moderators: Jarkko Rautio and Ken Sloan
- Facilitating Parent-Prodrug R&D and Regulatory Approval Roundtable, October 30,
2006
Panel members: Yuanchao Zhang, Mary Beth Wire, Reza Oliyai
Moderators: Tycho Heimbach and Paul Erhardt
JOIN THE PRODRUG FOCUS GROUP
To join the Prodrug Focus Group, click
here.
Back To Top
|
